Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
HealthDay News — For women with SARS-CoV-2 in pregnancy, vaccination after recovery is associated with increased odds of detectable immunoglobulin (Ig)G in infants, according to a study published online September 9 in The Journal of Infectious Diseases.
Mary C. Cambou, MD, from the University of California, Los Angeles, and colleagues conducted a study in a longitudinal cohort of pregnant women with SARS-CoV-2 infection. Maternal/infant sera were obtained at enrollment (from 256 pregnant women and 135 infants), delivery/birth (148 maternal and 122 neonatal specimens), and six months (45 maternal and 48 infant specimens).
The researchers found that 68% of women produced all anti-SARS-CoV-2 isotypes at delivery (IgG, IgM, and IgA); 96% had one or more isotype. Higher maternal IgG at labor and delivery was seen in association with symptomatic disease and vaccination before delivery. There was a decrease in detectable IgG in infants, from 78% at birth to 52% at 6 months. Significant predictors of detectable IgG in infants at delivery included third-trimester infection, mild/moderate disease, severe/critical disease, and maternal vaccination before delivery (odds ratios, 4.0, 4.8, 6.3, and 18.8, respectively). At 6 months postpartum, no factors were significant.
“Vaccination following infection and prior to delivery was the strongest predictor of infant antibodies at birth. Notably, infant levels dropped significantly by 6 months, emphasizing the importance of starting the COVID vaccine series as early as 6 months,” Cambou said in a statement.
Abstract/Full Text (subscription or payment may be required)
